Ποια είναι η τιμή για Sorrento Therapeutics, Inc. (0L85)

Η τιμή για Sorrento Therapeutics, Inc. (0L85) είναι $0.0033

Ποια είναι η κεφαλαιοποίηση αγοράς για Sorrento Therapeutics, Inc. (0L85)

Η κεφαλαιοποίηση αγοράς για Sorrento Therapeutics, Inc. (0L85) είναι $1.79M

Sorrento Therapeutics, Inc. (0L85) Τιμή και Κεφαλαιοποίηση Αγοράς

Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both clinical development and commercialization, dedicated to creating treatments across a broad spectrum of illnesses, including cancer, autoimmune conditions, inflammatory disorders, viral infections, and neurodegenerative diseases. The company conducts its operations through two distinct divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library alongside sophisticated targeted delivery methods. These include chimeric and dimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates, and bispecific antibody strategies. Additionally, its Sofusa drug delivery system enables the direct administration of biologics into the lymphatic system. Sorrento's pipeline features several clinical-stage programs. These encompass an anti-CD38 CAR-T therapy targeting multiple myeloma, amyloidosis, and graft-versus-host disease. The company is also advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, for managing pain associated with late-stage cancer and osteoarthritis of the knee. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. In the realm of pain management, SEMDEXA, an injectable viscous gel, is undergoing Phase III trials for sciatica (a form of lower back pain); SP-103, an experimental non-aqueous lidocaine topical system, is being developed for chronic low back pain; and SP-104 is a novel, low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. The company maintains several strategic collaborations, including a partnership with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical trial involving up to 94 COVID-19 patients. Additionally, Sorrento works with Mount Sinai Health System on COVI-SHIELD, an antibody treatment for SARS-CoV-2 infection, and with Mayo Clinic on a Phase Ib pilot study utilizing Sofusa technology for Ipilimumab delivery in melanoma patients. Established in 2006, Sorrento Therapeutics operates from its headquarters in San Diego, California.

Η τιμή για 0L85	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$10,037.36 $1.79M	NVDA	$5.452T	+304,162,384.59%
$8,266.52 $1.79M	AAPL	$4.490T	+250,500,417.86%
$7,663.35 $1.79M	GOOG	$4.162T	+232,222,712.92%
$6,768.47 $1.79M	MSFT	$3.676T	+205,104,921.85%
$5,215.88 $1.79M	AMZN	$2.833T	+158,056,794.65%

Η τιμή για 0L85

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$10,037.36 $1.79M